BioSpace News Archive

NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors for neuromuscular disorders, today announces that the first healthy volunteers have been dosed at the study site in London, UK.

Tonix Pharmaceuticals today announced the isolation and functional characterization of the two mirror image isomers of racemic tianeptine, which is marketed outside the U.S. as a treatment for major depressive disorder (MDD).

Zentalis ® Pharmaceuticals, Inc. today announced that the Company will host an investor update call to share the safety and efficacy results from its ongoing monotherapy dose optimization Phase 1 study of azenosertib, its potentially first-in-class WEE1 inhibitor product candidate.

Minghui Pharmaceutical, Inc., today announced that the phase 1a trial of MHB018A has commenced with the dosing of its first subject.

Prelude Corporation announced that a paper titled “Analytical Validation of the 7-gene Biosignature for Prediction of Recurrence Risk and Radiation Therapy Benefits for Breast Ductal Carcinoma in Situ” was published in Frontiers in Oncology.

Willow Biosciences Inc. and Kalsec® Inc. announce entry into a follow-on Master Services Agreement (the “MSA”) to develop an enzyme used in biocatalytic production of a new, advanced ingredient used in natural beverage applications.

Shanghai Junshi Biosciences Co., Ltd announced that the National Medical Products Administration has accepted the supplemental new drug application for the company’s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive untreated metastatic or recurrent metastatic triple-negative breast cancer.

Spago Nanomedical AB announced that the final step in the preparations for the clinical phase I/IIa trial in cancer patients, Tumorad-01, with its leading candidate drug 177Lu-SN201 has begun in Australia.

Veristat, a scientific-minded global clinical research organization and regulatory consultancy, shared the addition of three seasoned leaders to Veristat’s Executive team.

Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, announced multiple presentations to take place at the American Diabetes Association Annual Meeting from June 23–26, 2023 in San Diego, CA.